一种基于行动的概率框架,用于评估非变异性肝癌原体的剂量反应:PCB-126的案例研究
Yun Zhou1, Qiran Chen2, James E Klaunig1
1Department of Environmental and Occupational Health, School of Public Health-Bloomington, Indiana University, Bloomington, Indiana 47405, USA.
概括
这项研究引入了一个新的框架,将生物途径纳入化学风险评估. 它可以更准确地估计安全的化学物质剂量,改善对潜在致癌物质的公共卫生保护.
科学领域:
- 环境健康科学 环境健康科学
- 毒理学 毒理学 毒理学
- 风险评估 风险评估
背景情况:
- 目前的化学风险评估依赖于癌症和非癌症影响的单独策略,经常忽视关键的作用模式 (MOA) 信息.
- 现有的剂量反应评估方法因其二分化方法和缺乏与生物途径数据的整合而受到批评.
研究的目的:
- 开发一种新的,基于MOA的概率剂量反应框架,用于估计化学风险,特别是对具有致癌潜力的物质.
- 在剂量反应建模过程中量化合成生物途径信息,以提高风险评估的准确性.
主要方法:
- 该研究概述了一个基于MOA的四步建模框架:确定关键可量化的事件 (KQEs),计算基本剂量,基于MOA的出发点 (POD) 导出,以及基于MOA的概率参考剂量 (RfD) 估计.
- 该方法使用3,3',4,4',5-五二 (PCB-126) 进行了示例,以证明其应用和有效性.
主要成果:
- 基于MOA的POD和从新框架中得出的概率RfD与传统估计相比,被发现是可比和可信的.
- 该框架有效地整合了整个剂量连续的整体MOA信息,包括低剂量区域,提供了更全面的剂量反应关系.
- 可能性的RFD通过考虑不确定性和可变性,为人口健康保护提供了有价值的见解.
结论:
- 拟议的基于MOA的概率框架通过整合生物见解,对当前的化学风险评估方法进行了显著改进.
- 这种方法有可能广泛应用于各种化学品类型,而不仅仅是非变异性致癌物,从而提高了风险评估的有用性.
- 该框架能够提供概率性的健康保护见解,使其成为保护公共健康的宝贵工具.
更多相关视频
11:06Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.5K
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
13.9K
相关概念视频
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
01:03Dose-Response Relationship: Overview
3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
01:22Dose-Response Relationship: Potency and Efficacy
4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
01:25Dose-Response Relationship: Selectivity and Specificity
6.9K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.9K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
147
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
147